DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 5102--------------------------------------------------
       (Abst.)  Risk of postpartum disease activity with subcutaneous v
       s. IV natalizumab in pregnant women w/MS
       By: agate Date: March 2, 2026, 12:42 am
       ---------------------------------------------------------
       From PubMed (March 1, 2026)--"Risk of postpartum disease
       activity with subcutaneous versus intravenous natalizumab in
       pregnant women with multiple sclerosis":
  HTML https://pubmed.ncbi.nlm.nih.gov/41762952/
       *****************************************************